We revealed that FBXW7 effectively abated the expression and release of HMGB1, thereby suppressing TLR4 and RAGE signaling to attenuate inflammation and consequent insulin resistance, ultimately ameliorating NAFLD. This evidence concerns the gene AGER and metabolic dysfunction-associated steatotic liver disease.